MARKET

AFMD

AFMD

Affimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.03
-0.53
-8.08%
After Hours: 6.10 +0.07 +1.16% 17:34 01/26 EST
OPEN
6.56
PREV CLOSE
6.56
HIGH
6.59
LOW
6.00
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
7.48
52 WEEK LOW
1.420
MARKET CAP
633.11M
P/E (TTM)
-9.8885
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters Option to Purchase Additional Shares
Heidelberg, Germany, January 15, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the closing of its previously...
GlobeNewswire · 01/15 14:21
Affimed (AFMD) Catches Eye: Stock Jumps 8.8%
Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zacks · 01/14 13:36
Affimed (AFMD) Catches Eye: Stock Jumps 8.8%
Zacks.com · 01/14 11:29
Grubhub, Big Lots leads the premarket losers' pack
Marathon Patent Group (MARA) -19% after $250M capital raise.Zomedica (ZOM) -16%.Asia Pacific Wire & Cable Corporation (APWC) -16%.Harbor Custom Development (HCDI) -13% after pricing stock offering.Party City Holdco (PRTY) -12% after Q4 guidance falls short.Borr Drilling
Seekingalpha · 01/13 13:47
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12)
Benzinga · 01/13 12:25
Affimed drops 9% after pricing equity offering
Affimed (AFMD) has priced its public offering of ~16.7M common shares at $6.00/share.Expected net proceeds are ~$94M.Underwriters' over-allotment is an additional 2.5M shares.Closing date is January 15.Shares down 9% premarket.Previously, Jan.12: Affimed
Seekingalpha · 01/13 11:21
Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares
Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously...
GlobeNewswire · 01/13 11:15
MTRX, FARM, PRTY and QLI among after-hours movers
Gainers: [[MTRX]] +24.8%. [[FARM]] +19.1%. [[STIM]] +15.9%. [[EXFO]] +13.1%. [[FSI]] +11.1%.Losers: [[PRTY]] -12.3%. [[QLI]] -9.2%. [[URBN]] -7.8%. [[PRVB]] -7.4%. [[AFMD]] -5.6%.
Seekingalpha · 01/12 22:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AFMD. Analyze the recent business situations of Affimed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AFMD stock price target is 9.65 with a high estimate of 11.06 and a low estimate of 8.04.
EPS
Institutional Holdings
Institutions: 133
Institutional Holdings: 53.60M
% Owned: 51.05%
Shares Outstanding: 104.99M
TypeInstitutionsShares
Increased
35
5.35M
New
19
185.23K
Decreased
32
6.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman - Supervisory/Independent Director
Thomas Hecht
President/Management Board
Denise Mueller
Chief Executive Officer/Management Board
Adi Hoess
Chief Financial Officer
Angus Smith
Chief Operating Officer/Management Board
Wolfgang Fischer
Chief Scientific Officer/Management Board
Arndt Schottelius
Management Board
Andreas Harstrick
Independent Director/Supervisory Board
Bernhard Ehmer
Independent Director/Supervisory Board
Ulrich Grau
Independent Director/Supervisory Board
Berndt Modig
Independent Director/Supervisory Board
Mathieu Simon
Independent Director/Supervisory Board
Ferdinand Verdonck
Supervisory Board
Annalisa Jenkins
Supervisory Board
Harry Welten
  • Dividends
  • Splits
  • Insider Activity
No Data
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.